LataMed AI Seeks FINRA Approval for Forward Stock Split Amid Latin America Expansion
LataMed AI Corp. plans a 5-for-1 forward stock split to support operational scalability and growth as it deploys telehealth infrastructure in Latin America.
LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on emerging markets, announced it expects to formally submit a corporate action request to FINRA today for approval of a proposed five-for-one forward stock split, along with proportional increases in authorized common and preferred stock. The move is intended to support broader long-term operational scalability, strategic flexibility, and future growth initiatives as the company advances telehealth infrastructure deployment and healthcare analytics integration throughout Latin America and other targeted markets.
The proposed corporate action would apply proportionally to all issued and outstanding shares of common stock and outstanding preferred stock designations, including the Series C Voting Preferred Stock. The company emphasized that the split does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected; any fractional interests would be rounded up to the nearest whole share pursuant to board resolutions.
Management stated that the forward stock split is part of a broader effort to align the company’s capital structure with its ongoing transition into digital healthcare infrastructure and AI-driven telehealth operations. Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., said: “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The company recently commenced initial operational activities for its telehealth platform in Venezuela after receiving regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This marks a key milestone in LataMed’s strategy to deploy scalable telehealth infrastructure in emerging markets, where access to healthcare services is often limited.
The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. The company noted that no assurance can be provided regarding the timing or ultimate effectiveness of the proposed action. Investors can review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov for more details.
LataMed AI Corp. is a development-stage enterprise that has not generated revenues from its current business operations. The company is positioning itself to participate in the modernization and digital transformation of healthcare delivery systems across emerging markets through telehealth infrastructure development, AI-driven technologies, regulatory progression, and strategic partnerships.